Striated muscle myosin heavy chain is a molecular motor protein that converts chemical energy into mechanical force. It is a major determinant of the physiological properties of each of the three muscle fibre types that make up the skeletal muscles. Heterozygous dominant missense mutations in myosin heavy chain genes cause various types of cardiomyopathy and skeletal myopathy, but the effects of myosin heavy chain null mutations in humans have not previously been reported. We have identified the first patients lacking fast type 2A muscle fibres, caused by total absence of fast myosin heavy chain IIa protein due to truncating mutations of the corresponding gene MYH2. Five adult patients, two males and three females, from three unrelated families in UK and Finland were clinically assessed and muscle biopsy was performed in one patient from each family. MYH2 was sequenced and the expression of the corresponding transcripts and protein was analysed in muscle tissue. The patients had early-onset symptoms characterized by mild generalized muscle weakness, extraocular muscle involvement and relatively favourable prognosis. Muscle biopsy revealed myopathic changes including variability of fibre size, internalized nuclei, and increased interstitial connective and adipose tissue. No muscle fibres expressing type IIa myosin heavy chain were identified and the MYH2 transcripts were markedly reduced. All patients were compound heterozygous for truncating mutations in MYH2. The parents were unaffected, consistent with recessive mutations. Our findings show that null mutations in the fast myosin heavy chain IIa gene cause early onset myopathy and demonstrate that this isoform is necessary for normal muscle development and function. The relatively mild phenotype is interesting in relation to the more severe phenotypes generally seen in relation to recessive null mutations in sarcomeric proteins.
Introduction
Myosin is one of the most abundant proteins in the body and is indispensable for body movement and heart contractility. Three major myosin heavy chain (MyHC) isoforms are present in adult human limb skeletal muscle: MyHC I, also called slow/b-cardiac MyHC, is the gene product of MYH7 and is expressed in slow, type 1 muscle fibres as well as in the ventricles of the heart; MyHC IIa (MYH2) is expressed in fast, type 2A muscle fibres; and MyHC IIx (MYH1) is expressed in fast, type 2B muscle fibres. The three different muscle fibre types display distinct physiological properties and have unique roles in the function of skeletal muscle (Larsson and Moss, 1993) . We describe the clinical and morphological characteristics of patients from three unrelated families lacking the production of MyHC IIa due to non-sense and truncating mutations in MYH2.
Materials and methods

Patients
Five patients were clinically assessed (Table 1) . Three of the patients had mild to moderate generalized muscle weakness from early childhood, with minor progression. Two were subjectively asymptomatic. All had facial muscle weakness and marked external ophthalmoplegia and two had ptosis.
Muscle morphology
Muscle biopsy specimens were obtained from one patient of each family. In Patient II:1 (Family A) muscle biopsy specimens were obtained from the vastus lateralis of the quadriceps femoris muscle, at age 38, and from the deltoid muscle at age 40. In Patient II:2 (Family B) and Patient II:1 (Family C) muscle biopsies were obtained from the vastus lateralis of the quadriceps femoris muscle at age 55 and 58, respectively. Enzyme and immunohistochemical analyses, including MyHC isoforms, of freshly frozen muscle biopsy specimens were performed as previously described (Tajsharghi et al., 2002) . In Patients II:2 (Family B) and II:1 (Family C) a new double immunostaining method for MyHC isoforms was performed that shows the expression of different MyHC isoforms in different muscle fibres in a single section (Raheem et al., 2010) .
DNA analysis
Genomic DNA was extracted from frozen skeletal muscle or peripheral blood using DNA Extraction Kit (Qiagen, Hilden, Germany). Polymerase chain reaction (PCR) analysis was performed in a master mixture (ReddyMix PCR Master Mix; Abgene, Epsom, UK) after addition of 20 pmol of each primer and genomic DNA. PCR amplifications were performed as previously described (Tajsharghi et al., 2005) . Nucleotide sequence determination was performed by cycle sequencing using a BigDye Terminator DNA sequencing kit (Applied Biosystems, Hercules, CA).
RNA analysis
The complementary DNA of MyHC isoforms, including the three adult skeletal isoforms, are highly homologous. In order to solely amplify fragments of MYH2 by PCR, we performed alignment of MYH2, MYH1, MYH7, MYH4, MYH3 and MYH8 complementary DNA (http://bio.lundberg.gu.se/edu/msf.html) to design MYH2 specific primers. Total RNA was extracted from muscle tissue of the patients using the Total RNA Isolation System (Promega, Madison, WI). Synthesis of first-strand complementary DNA was performed using Ready-To-Go You-Prime First-Strand Beads (Amersham Pharmacia Biotech, Uppsala, Sweden) according to the manufacturer's instructions using 1 mg total RNA.
To analyse the splicing of exon 8 of MYH2 in Patient II:1 (family A), PCR was performed on complementary DNA with forward primer AGTGACGGTGAAGACTGAGGGA (corresponding to nucleotide 177-198 of human MyHC IIa complementary DNA sequence) combined with a backward primer ATCTGTGGCCATCAGTTCTTCCT (corresponding to nucleotide 986-1008 of human MyHC IIa complementary DNA). The resulting PCR products were analysed by sequencing after separation on 2% agarose gel and purification using QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany). To analyse the proportion of transcripts of the three major MyHC isoforms, PCR was performed on complementary DNA extracted from skeletal muscle and fragment analysis was performed as previously described (Tajsharghi et al., 2002) .
Protein analysis
To analyse the expression of the MyHC isoforms, proteins extracted from muscle biopsy specimens were separated by 8% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) as previously described (Tajsharghi et al., 2002) .
Haplotype analysis
Haplotype analysis was performed with micro-satellite markers. 
Results
Laboratory investigations
Morphological analysis of biopsy specimens from the quadriceps femoris and deltoid muscles of Patient II:1 (Family A) demonstrated type 1 fibre uniformity in the deltoid muscle and absence of type 2A fibres in both muscles ( Fig. 1) . A biopsy specimen from vastus lateralis of the quadriceps femoris muscle of Patient II:2 (Family B) demonstrated absence of MyHC IIa and myopathic features including increased variability of fibre size and internalized nuclei (Fig. 2) . In Patient II:1 (Family C) a muscle biopsy of the vastus lateralis of the quadriceps muscle showed absence of muscle fibres expressing type IIa MyHC, as well as myopathic changes that included marked variability in fibre size, internalized muscle fibre nuclei, increased interstitial fat and connective tissue and type 1 fibre uniformity (Fig. 3A-C) . MRI or CT of skeletal muscle in two of the patients showed diffuse fatty infiltration with an unusual pattern of predominant involvement of medial gastrocnemius in the lower legs, combined with predominant involvement of the semitendinosus, gracilis and vastus lateralis muscles in the thigh. The tibialis anterior muscle, which mainly consists of slow muscle fibres, showed normal appearance ( Fig. 3D-G ).
Molecular genetics
The incentive to consider mutated MYH2 as a plausible cause of the disease was the ophthalmoplegia in the patients of Family A since in skeletal myopathy associated with a dominant missense mutation, p.E706K in MYH2, all patients had ophthalmoplegia and abnormal type 2A muscle fibres (Martinsson et al., 2000) . In Families B and C it was the total absence of fast IIa fibres with the new double immunostaining technique (Raheem et al., 2010) in proximal muscle biopsy specimens that indicated a MYH2 defect.
Mutation analysis of MYH2 was performed in six individuals. In Patient II:1 (Family A), we identified two sequence variants. the reading frame and a premature stop codon (p. Tyr269-Glu302delfsX) (Fig. 4B) . The second variant was a heterozygous nonsense mutation, c.2347C4T, changing Arginine at position 883 to a stop codon (p.Arg783X) in exon 19 (Fig. 4C) . The same two mutations were also identified in siblings II:2 and II:3 (Family A). 
Analysis of MYH2 transcripts
To determine the effect of the mutations on MYH2 gene expression, analysis of the relative level of expression of different isoforms of MyHC mRNA was performed by PCR on complementary DNA and fragment analysis. These results demonstrate that the three patients express very low levels of MYH2 transcripts (Fig. 5A ).
Protein analysis
The expression of MyHC isoforms by SDS-PAGE analysis of the deltoid muscle of Patient II:1 (Family A) and the quadriceps muscle (Fig. 5B ). There was a predominant expression of slow/ b-cardiac MyHC (MyHC I) in these two muscle biopsy specimens.
Haplotype analysis
Haplotype analysis of Patient II:2 (Family B) and Patient II:1 (Family C) revealed that the two patients carried the identical haplotype over a distance 3.3 Mb on one chromosome with the c.1975-2A4G mutation, whereas sharing of a shorter segment (0.7-1.5 Mb) on the other chromosome indicates that the c.2405T4A mutation was more ancient.
Discussion
We have identified the first patients with loss of a MyHC isoform, MyHC IIa and complete loss of one of the major muscle fibre types, type 2A. recessive and that hemizygous loss of MyHC IIa expression does not lead to haploinsufficiency and disease. In human limb muscle there are two fast MyHC isoforms: MyHC IIa (corresponding to MyHC IIa in the mouse) and MyHC IIx (corresponding to MyHC IId/x in the mouse). Mice also express a third fast MyHC isoform in limb skeletal muscle: MyHC IIb. Results from studies on MyHC IId/x and MyHC IIb null mice demonstrate that these genes are required for the normal muscle development and function of adult skeletal muscle in the mouse and that the different fast MyHC isoforms are functionally unique and cannot substitute for one another (Acakpo-Satchivi et al., 1997; Sartorius et al., 1998; . MyHC IIa null mice have been reported but not characterized in detail (Geurts et al., 2006) .
Our patients with loss of fast MyHC IIa expression exhibited muscle weakness and myopathic changes with predominant involvement of semitendinous, gracilis, vastus lateralis and medial gastrocnemius muscles in the lower limbs. The reason for preferential involvement of these muscles remains to be demonstrated but may reflect the relative proportion of MyHC IIa in these muscles, since the tibial anterior muscle, which is predominantly composed of slow fibres, showed normal appearance on imaging. In MyHC IIb knockout mice, two factors appeared to determine the extent to which a muscle was affected: the level of MyHC IIb and the amount of muscle activity (Allen et al., 2000) . In the MyHC IId/x null mice there was no such correlation suggesting that other factors may also be of importance (Allen et al., 2000) .
The expression of MyHC IIa can be detected from around 24 weeks gestational age to adulthood in humans and it is one of the major MyHC isoforms expressed in human skeletal muscle (Butler-Browne et al., 1990; Cho et al., 1994; Smerdu et al., 1994) . This implies that our patients had disturbed development and maturation of skeletal muscle from around 24 weeks of gestational age, which is consistent with the early onset of symptoms. However, none of the patients were identified at birth as having a congenital myopathy. Analogous with the MyHC IIb and IId/x null mice, our patients showed slow progression of muscle wasting with increasing age (Acakpo-Satchivi et al., 1997; . As in mice, the progression may be related to ongoing degeneration and regeneration as indicated by the pathological changes in muscle biopsy specimens. Why degenerative changes in the type 1 and type 2B fibres occur when one MyHC isoform and fibre type is lacking is not clear. A possible explanation could be that proper maintenance of muscle tissue requires all myosin isoforms and fibre types, and that muscle fibre degeneration is a consequence of less capability to sustain mechanical load during normal activity if one fibre type is lost.
The explanation of the apparent type 1 fibre uniformity and predominant expression of slow myosin in two of the investigated muscles (deltoid muscle of Patient II:1 in Family A and quadriceps muscle of Patient II:1 in Family C) is not clear. It is well known that in many congenital or early onset myopathies, such as nemaline myopathy and central core disease, there is predominance and sometimes uniformity of type 1 fibres. However, in our patients, type 1 fibre predominance was not a consistent finding in all muscles since Patient II:1 (Family A) had a normal amount of type 2B fibres in the quadriceps muscle and Patient II:2 (Family B) expressed MYH1 gene transcript at a nearly normal level in the quadriceps muscle, and up to 15% of fibres expressed MyHC IIx on immunohistochemistry. In the quadriceps muscle the normal proportion of type 1 fibres is between 44 and 57% (Lexell et al., 1983) .
The clinical phenotype of our patients with compound heterozygous null mutations of MYH2 was rather mild. This was unexpected since several other myopathies caused by recessive null mutations of sarcomeric proteins that exist in different isoforms show a much more severe clinical phenotype. Absence of -tropomyosin slow (TPM3) (Tan et al., 1999) or muscle troponin T slow (TNNT1) (Jin et al., 2003) is associated with severe forms of nemaline myopathy. Complete loss of b-tropomyosin (TPM2) is associated with Escobar syndrome with nemaline myopathy (Monnier et al., 2009 ) and absence of -skeletal muscle actin (ACTA1) is associated with persistent expression of developmental actin and severe or intermediate nemaline myopathy (Nowak et al., 2006) . In addition, the various isoforms of skeletal muscle MyHC genes and proteins show a high degree of conservation in genomic structure and amino acid sequences. The orthologous isoforms of MyHC in different species have a greater extent of conservation than different isoforms within a species (Weiss et al., 1999) suggesting an important functional diversity within the MyHC gene family.
The fact that MyHC IIa is expressed in extraocular muscle can explain the ophthalmoplegia observed in all of our patients (Pette and Staron, 1997; Pedrosa-Domellö f et al., 2000). In patients with autosomal dominant myopathy associated with the heterozygous MYH2 p.E706K missense mutation, there was a clear correlation between pathology and expression of MyHC IIa indicating a dominant negative effect of this missense mutation (Tajsharghi et al., 2002) . In the patients with no fast IIa MyHC due to compound heterozygous truncating MYH2 mutations, the situation is different and illustrates the importance of expression of MyHC IIa, even if hemizygous loss is well tolerated. Total absence of MyHC IIa cannot be substituted for by an increased expression of another MyHC isoform but the consequence of the total loss is a surprisingly mild phenotype.
